Skip to main content

Knight Therapeutics Completes the Tender Offer for Grupo Biotoscana And Achieves Over 95% Ownership

Written by Customer Service on . Posted in Public Companies.

MONTREAL, Aug. 14, 2020 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight“), a leading pan-American (ex-US) specialty pharmaceutical company, today announced the results of the tender offer process (“Tender Offer”) for the acquisition of all outstanding Brazilian Depositary Receipts (“BDRs”) of Biotoscana Investments S.A. (“GBT”). A total of 49,778,512 of BDRs were tendered by BDR holders thereby resulting in Knight owning 98% of all outstanding GBT shares and BDRs. The settlement of the Tender Offer shall occur on August 18, 2020 (“Settlement Date”). On the Settlement Date, Knight will payout a total of R$517,837,423.
Based on the results provided by B3 S.A. – Brasil, Bolsa, Balcão on the date hereof: (a) 169,757 BDRs were tendered at the Offer Price. Accordingly, Knight shall pay R$11.23 per BDR to the BDR Holders that chose this price, provided that (i) R$8.98 per BDR will be paid on the Settlement Date, in cash; and (ii) R$2.25 per BDR will be deposited in an escrow account for the benefit of such BDRs Holders, and further provided that the amount of R$0.91 shall be mandatorily paid at any time prior to November 29, 2022, as adjusted by SELIC from the Settlement Date until the payment date; and (b) 49,608,755 BDRs were tendered at the Alternative Offer Price. Accordingly, Knight shall pay R$10.40 per BDR on the Settlement Date, in cash, to the BDR Holders that chose this price.Considering that, on the Settlement Date, the remaining outstanding BDRs will represent less than five per cent (5%) of the total capital stock of GBT (taking into consideration BDRs and common shares), Knight approved, on the date hereof, the squeeze out of the remaining BDRs, as provided for in the Notice (“Squeeze-Out”).In accordance with the Notice, the BDR Holders will have three (3) days (“Deadline Squeeze-Out”) from the date hereof to elect to receive the final auction value of the Offer Price or the Alternative Offer Price, adjusted by the Selic Rate, calculated pro rata temporis from the Settlement Date until the date of deposit. Knight has the right to buy BDRs at the Alternative Offer Price from BDR Holders who fail to provide the necessary documents and information within the Deadline Squeeze-Out.Following the Squeeze-Out, Knight will proceed with delisting GBT in Brazil and Luxembourg.About Knight Therapeutics Inc.Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pan-American (ex-US) specialty pharmaceutical company focused on developing, acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns a controlling stake in Grupo Biotoscana, a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.gud-knight.com or www.sedar.com.Forward-Looking StatementThis document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2019 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.Contact Information for Knight:Knight Therapeutics Inc.
Samira Sakhia
President and Chief Operating Officer
T: 514-678-8930
F: 514-481-4116
Email: info@gudknight.com  
Website: www.gud-knight.comKnight Therapeutics Inc.
Arvind Utchanah
Chief Financial Officer
T. 514.484.4483 ext. 115
F. 514.481.4116
Email: info@gudknight.com 
Website: www.gud-knight.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.